Please assess the completion status of the following clinical trial:

Trial Title: ARTS - AVODART After Radical Therapy For Prostate Cancer Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients eligible for enrolment in the study must meet all of the following criteria:~* Males \<85 years of age~* No clinically relevant abnormal findings on the screening ECG~* Patients with asymptomatic PSA failure following radical therapy with curative intent for clinically localised prostate cancer. PSA failure is defined as:~* After primary radiotherapy:~* 3 rises in PSA levels from nadir PSA, with each determination at least 4 weeks apart and a final PSA level ≥2 ng/mL above nadir PSA~* Time from radiotherapy should be at least 1 year from termination of radiotherapy treatment~* After radical prostatectomy with or without salvage radiotherapy:~* 3 rises in PSA level from nadir PSA, with each determination at least 4 weeks apart and each PSA level ≥0.2 ng/mL and a final PSA level ≥0.4 ng/mL (nadir PSA is defined as the lowest PSA value achieved after therapy)~* Serum PSA levels:~* ≥2 ng/mL and ≤20ng/mL for primary radiotherapy patients~* ≥0.4 ng/ml and ≤10ng/ml for radical prostatectomy with or without salvage radiotherapy patients~* PSADT \>3 months and ≤24 months~* Clinical stage T1-T3a N0 M0~* Non-metastatic prostate cancer, as confirmed on a negative bone scan performed within 6 months prior to randomisation (Visit 2)3.~* No evidence of local recurrence in radical prostatectomy or salvage radiotherapy patients~* Expected survival ≥2 years~* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 (see Appendix 1)~Miscellaneous:~* Able to swallow and retain oral medication~* Able and willing to participate in the full 2 years of the study~* Able to read and write (the MAX-PC questionnaire is self-administered), understand instructions related to study procedures and give written informed consent~* In France, a patient will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.~Exclusion Criteria:~* Any unstable serious co-existing medical condition(s) including but not limited to myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure or cerebrovascular accident within 6 months prior to Visit 1, or uncontrolled diabetes or peptic ulcer disease which is uncontrolled by medical management~* Abnormal liver function tests (greater than 2 times the upper limit of normal \[ULN\] for alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] or alkaline phosphatase \[ALP\] or \>1.5 x ULN for bilirubin).~* Serum creatinine \>1.5 x ULN~* History of another malignancy within 5 years that could affect the diagnosis of prostate cancer~* History or current evidence of drug or alcohol abuse within 12 months prior to Visit 1~* History of any illness (including psychiatric) that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient~* Known hypersensitivity to any 5-AR inhibitor or to any drug chemically related to dutasteride~Disease characteristics:~* Serum PSA levels~* \>20 ng/mL in primary radiotherapy patients~* \>10 ng/mL in radical prostatectomy with or without salvage radiotherapy patients~* PSADT ≤3 months or \>24 months~* Biochemical failures in post brachytherapy patients~* Clinical stage N+ or M+~* Patient has previously been treated for prostate cancer with any of the following:~* Chemotherapy~* Oestrogens (e.g. megestrol, medroxyprogesterone, cyproterone, Diethylstilbestrol \[DES\])~* Drugs with anti-androgenic properties (e.g. spironolactone if \>50mg/day, flutamide, bicalutamide, ketoconazole, progestational agents), (except when used for adjuvancy or neoadjuvancy in the context of a primary radical treatment in which case their use should have been for no more than 6 months and should have completed at least 1 year before Visit 1 \[Note: the use of topical ketoconazole is permitted prior to and during the study and the use of cimetidine is permitted prior to study entry\]~* GnRH analogues (e.g., leuprolide, goserelin) except when used for adjuvancy or neoadjuvancy in the context of a primary radical treatment (in this case use should have been for no more than 6 months and should have finalised at least 1 year before Visit 1)~* Orchiectomy~Concomitant medications:~* Glucocorticoids, except inhaled or topical, are not permitted within 3 months prior to Visit 1 or during the study~* Current and/or previous use of finasteride (Proscar, Propecia) or dutasteride (GI198745, AVODART™) exposure within 6 months prior to Visit 1~* Anabolic steroids within 6 months prior to Visit 1~* Participation in any other investigational or marketed drug trial within the 30 days prior to Visit 1 or any time during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Avodart (Type: EXPERIMENTAL): Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
- Placebo Arm (Type: PLACEBO_COMPARATOR): Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete